Table 1.
Clinical studies with multimeric c(RGD) molecules.
| Imaging Agent | Year | # Patients | Confirmation | Neoplasm | Ref. |
|---|---|---|---|---|---|
| [18F]FP-PRGD2 PET/C 8 |
2014 | 8 | HP | BCa | [73] |
| [18F]Alfatide I 10 |
2015 | 26/16 | HP | LCa/Lnd | [76] |
| [18F]Alfatide I PET/CT 10 |
2017 | 13 | HP | Lnd | [77] |
| [18F]Alfatide II PET/CT 14 |
2015 | 5 (HV) 9 |
MRI/CT | BrCa | [54] |
| [18F]Alfatide II PET/CT 14 |
2015 | 30 | BnCa | [53] | |
| [18F]Alfatide II PET/CT 14 |
2018 | 44 | HP | BCa | [52] |
| [68Ga]Ga-NOTA-PRGD2 PET/CT 12 |
2015 | 91 159 |
HP | Lnd | [78] |
| [68Ga]Ga-RGD2 PET/CT 15 |
2017 | 31 (21/10) | HP | NSCLC/SCLC | [79] |
| [68Ga]Ga-RGD2 PET/CT 15 |
2016 | 21/13 | HP | NSCLC/TB | [51] |
Abbreviations used: HP: Histopathology; Lnd: Lymph nodes; BCa: breast cancer; LCa: lung cancer; BrCa: Brain cancer; BnCa: Bone Cancer; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; TB: tuberculosis.